Matrix Capital Management Co. LP recently announced the acquisition of new stake in Adaptimmune Therapeutics plc (NASDAQ:ADAP). The institutional investor has increased its shareholding in the Healthcare company by 13.20% to 38.97 million shares with purchase of 4.55 million shares. This fresh investment now brings its stake to 25.36% valued currently at $364.41 million. In addition, RA Capital Management LLC raised its holdings by 0.51 million to 13.05 million shares.
With over 1.46 million Adaptimmune Therapeutics plc (ADAP) shares trading Friday and a closing price of $7.92 on the day, the dollar volume was approximately $11.57 million. The shares have shown a negative weekly performance of -6.05% and its price on 08/28/20 lost nearly -2.70%. Currently, there are 137.12M common shares owned by the public and among those 11.20M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 8 analysts who have offered their price forecasts for ADAP have a consensus price objective of $12.67. The analysts have set the share’s price value over the next 12 months at a high of $17.00 and a low of $9.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Adaptimmune Therapeutics plc stock is 2.40 for the next 12 months. The average price target is 37.49% above its last price level and an upside to the estimated low will see the stock gain 12.0% over that period. But an upside of 53.41% will see the stock hit the forecast high price target while mean target price for the stock is $12.50.
Insiders at the company have transacted a total of 6 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 6 of these insider trades were purchases, accounting for 45,000,000 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Adaptimmune Therapeutics plc are American Funds Small Cap World Fu, Baillie Gifford Overseas Growth F, and Victory RS Small Cap Growth Fund. American Funds Small Cap World Fu owns 9.32 million shares of the company’s stock, all valued at over $87.18 million. Baillie Gifford Overseas Growth F bought 0.38 million shares to see its total holdings expand to 2.42 million shares valued at over $22.62 million and representing 1.57% of the shares outstanding. Victory RS Small Cap Growth Fund bought 1.07 million shares to bring its total holdings to over 1.07 million shares at a value of $9.96 million. Victory RS Small Cap Growth Fund now owns shares totaling to 0.69% of the shares outstanding.
Shares of Adaptimmune Therapeutics plc (NASDAQ: ADAP) opened at $8.07, down -$0.07 from a prior closing price of $8.14. However, the script later closed the day at $7.92, down -2.70%. The company’s stock has a 5-day price change of -6.05% and -31.96% over the past three months. ADAP shares are trading 560.00% year to date (YTD), with the 12-month market performance up to 395.00% higher. It has a 12-month low price of $0.71 and touched a high of $13.40 over the same period. Currently, 1.46 million shares have been traded, compared to an average intraday trading volume of 3.08 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.56%, -11.87%, and 58.19% respectively.
Institutional ownership of Adaptimmune Therapeutics plc (NASDAQ: ADAP) shares accounts for 89.20% of the company’s 137.12M shares outstanding. Mutual fund holders own 14.30%, while other institutional holders and individual stakeholders account for 59.93% and 11.37% respectively.
It has a market capitalization of $1.26B and a beta (3y monthly) value of 2.05. The earnings-per-share (ttm) stands at -$1.10. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.41% over the week and 7.04% over the month.
Analysts forecast that Adaptimmune Therapeutics plc (ADAP) will achieve an EPS of -$0.25 for the current quarter, -$0.23 for the next quarter and -$0.98 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.29 while analysts give the company a high EPS estimate of -$0.23. Comparatively, EPS for the current quarter was -$0.36 a year ago. Earnings per share for the fiscal year are expected to decrease by -33.20%, and -7.70% over the next financial year. EPS should grow at an annualized rate of 1.00% over the next five years, compared to -46.40% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 8 brokerage firm advisors rate Adaptimmune Therapeutics plc (ADAP) as a “Moderate Buy” at a consensus score of 2.40. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 4 of the 8 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ADAP, a number of firms have released research notes about the stock. Mizuho stated their Neutral rating for the stock in a research note on April 22, 2020, with the firm’s price target at $3. Guggenheim coverage for the Adaptimmune Therapeutics plc (ADAP) stock in a research note released on August 02, 2019 offered a Neutral rating with a price target of. ROTH Capital was of a view on May 31, 2019 that the stock is Buy, while Citigroup gave the stock Buy rating on May 30, 2019, issuing a price target of. SVB Leerink on their part issued Mkt Perform rating on May 07, 2019.